BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 3884712)

  • 1. Combined ex vivo treatment with immunotoxins and mafosfamid: a novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts.
    Uckun FM; Stong RC; Youle RJ; Vallera DA
    J Immunol; 1985 May; 134(5):3504-15. PubMed ID: 3884712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-T cell immunotoxins containing pokeweed anti-viral protein: potential purging agents for human autologous bone marrow transplantation.
    Ramakrishnan S; Uckun FM; Houston LL
    J Immunol; 1985 Nov; 135(5):3616-22. PubMed ID: 3900212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates.
    Bregni M; De Fabritiis P; Raso V; Greenberger J; Lipton J; Nadler L; Rothstein L; Ritz J; Bast RC
    Cancer Res; 1986 Mar; 46(3):1208-13. PubMed ID: 3510720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elimination of clonogenic T-leukemic cells from human bone marrow using anti-Mr 65,000 protein immunotoxins.
    Stong RC; Youle RJ; Vallera DA
    Cancer Res; 1984 Jul; 44(7):3000-6. PubMed ID: 6372999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'-deoxycoformycin, deoxyadenosine and an immunotoxin.
    Montgomery RB; Kurtzberg J; Rhinehardt-Clark A; Haleen A; Ramakrishnan S; Olsen GA; Peters WP; Smith CA; Haynes BF; Houston LL
    Bone Marrow Transplant; 1990 Jun; 5(6):395-402. PubMed ID: 2369680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo elimination of lymphoblastic leukemia cells from human marrow by mafosfamid.
    Uckun FM; Ramakrishnan S; Haag D; Houston LL
    Leuk Res; 1985; 9(1):83-95. PubMed ID: 3887044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cellular sorting methods in autologous (elimination of residual malignant cells) or allogeneic (T lymphocyte elimination) bone marrow grafts. Clinical pilot studies].
    Hervé P; Flesch M
    Nouv Rev Fr Hematol (1978); 1986; 28(2):97-105. PubMed ID: 2942838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous bone marrow transplantation with marrow decontaminated by immunotoxin T 101 in the treatment of leukemia and lymphoma: first clinical observations.
    Gorin NC; Douay L; Laporte JP; Lopez M; Zittoun R; Rio B; David R; Stachowiak J; Jansen J; Cazellas P
    Cancer Treat Rep; 1985 Sep; 69(9):953-9. PubMed ID: 3896482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased efficiency in selective elimination of leukemia cells by a combination of a stable derivative of cyclophosphamide and a human B-cell-specific immunotoxin containing pokeweed antiviral protein.
    Uckun FM; Ramakrishnan S; Houston LL
    Cancer Res; 1985 Jan; 45(1):69-75. PubMed ID: 3871174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific ex-vivo depletion of human bone marrow T lymphocytes by an anti-pan-T cell (CD5) ricin A-chain immunotoxin.
    Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM
    Transplantation; 1987 Mar; 43(3):421-6. PubMed ID: 3103275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse L1210V leukemia as a model to analyse efficiency of leukemic cell elimination by immunotoxin, antibody and complement, and cytostatic agents.
    Paprocka M; Wiedlocha A; Radzikowski C
    In Vivo; 1990; 4(3):209-13. PubMed ID: 2133264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell depletion with ricin A-chain T101 in allogeneic bone marrow transplantation to prevent severe graft-versus-host disease.
    Fauser AA; Shustik C; Langleben A; Laurent G; Kanz L; Spurll GM; Price G; Ahlgren PD; Cooper BA
    Clin Invest Med; 1988 Feb; 11(1):40-6. PubMed ID: 3284672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological and pharmacological removal of small cell lung cancer cells from bone marrow autografts.
    Humblet Y; Feyens AM; Sekhavat M; Agaliotis D; Canon JL; Symann ML
    Cancer Res; 1989 Sep; 49(18):5058-61. PubMed ID: 2548708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of colony assays and anti-T cell immunotoxins to elucidate the immunobiologic features of leukemic progenitor cells in T-lineage acute lymphoblastic leukemia.
    Uckun FM; Myers DE; Ledbetter JA; Swaim SE; Gajl-Peczalska KJ; Vallera DA
    J Immunol; 1988 Mar; 140(6):2103-11. PubMed ID: 3126241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of multiple T cell-directed intact ricin immunotoxins for autologous bone marrow transplantation.
    Stong RC; Uckun F; Youle RJ; Kersey JH; Vallera DA
    Blood; 1985 Sep; 66(3):627-35. PubMed ID: 3896347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow.
    Uckun FM; Ramakrishnan S; Houston LL
    J Immunol; 1985 Mar; 134(3):2010-6. PubMed ID: 3855433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of an anti-CD7-ricin A chain immunoconjugate in a novel murine model of human T-cell leukemia.
    Fishwild DM; Aberle S; Bernhard SL; Kung AH
    Cancer Res; 1992 Jun; 52(11):3056-62. PubMed ID: 1375534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of mafosfamide (ASTA-Z-7654) on the clonogenic cells in precursor-B acute lymphoblastic leukaemia: significance for ex vivo purging of bone marrow for autologous transplantation.
    Makrynikola V; Kabral A; Bradstock KF
    Bone Marrow Transplant; 1991 Nov; 8(5):351-5. PubMed ID: 1768969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evaluation of combination drug purging for autologous bone marrow transplantation.
    Jones RJ; Miller CB; Zehnbauer BA; Rowley SD; Colvin OM; Sensenbrenner LL
    Bone Marrow Transplant; 1990 May; 5(5):301-7. PubMed ID: 2350626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement.
    Bast RC; De Fabritiis P; Lipton J; Gelber R; Maver C; Nadler L; Sallan S; Ritz J
    Cancer Res; 1985 Feb; 45(2):499-503. PubMed ID: 3967224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.